文献速递治疗药物监测与药物基因组学特殊人群用药

CYP2B6基因多态性与安非他酮及羟基安非他酮暴露的系统综述与荟萃分析

Association of CYP2B6 genetic polymorphisms with bupropion and hydroxybupropion exposure: A systematic review and meta-analysis.
PubMed 文献 · Pharmacotherapy · 2021-11-23

该系统综述与荟萃分析旨在量化CYP2B6变异等位基因及基因型定义的代谢表型与安非他酮及其活性代谢物羟基安非他酮(HB)暴露的关联。结果显示,CYP2B6*6携带者相比非携带者,HB和活性总部分的AUC显著降低;CYP2B6慢代谢型和中间代谢型相比正常代谢型,HB和活性总部分暴露也显著降低。结论提示CYP2B6*6等位基因及基因型确定的慢/中间代谢表型与HB和总活性部分暴露显著降低相关,为基于基因型的精准给药研究提供了机会。

要点

  • CYP2B6*6携带者HB暴露较非携带者降低(RoM 0.77,95%CI 0.71-0.83)。
  • CYP2B6*6携带者活性总部分暴露较非携带者降低(RoM 0.81,95%CI 0.75-0.88)。
  • CYP2B6慢代谢型和中间代谢型HB及活性总部分暴露均显著低于正常代谢型。

核心结论

  • CYP2B6*6等位基因及基因型确定的CYP2B6慢代谢和中间代谢表型与HB和总活性部分暴露显著降低相关。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、EMBASE、Web of Science、Scifinder、PsycINFO和CENTRAL(检索更新至2021年2月)。
  • 纳入标准为研究安非他酮和/或HB的AUC与CYP2B6基因型关系,且至少检测CYP2B6*6等常见变异等位基因。

主要发现

  • CYP2B6*6携带者相比非携带者,HB的AUC显著降低(RoM 0.77,95%CI 0.71-0.83)。
  • CYP2B6*6携带者相比非携带者,活性总部分(安非他酮+HB)的AUC显著降低(RoM 0.81,95%CI 0.75-0.88)。
  • CYP2B6慢代谢型和中间代谢型相比正常代谢型,HB和活性总部分暴露均显著降低。

临床怎么用

  • 临床可关注CYP2B6*6等位基因及慢/中间代谢表型患者,其安非他酮活性代谢物暴露可能偏低。
  • 研究结果提示可进一步研究基于CYP2B6基因型的安非他酮精准给药策略。

局限性

  • 纳入荟萃分析的10项研究均为健康成人志愿者,不允许合并其他用药,外推至临床患者需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Bupropion is metabolized to its active metabolite, hydroxybupropion (HB), by the genetically polymorphic cytochrome P450 2B6 (CYP2B6) enzyme. Despite its significant role in bupropion metabolism, the magnitude of the impact of CYP2B6 genotype on the exposure of bupropion has not been quantified. OBJECTIVES: A systematic review and meta-analysis was conducted to quantify the association of bupropion and HB exposure with CYP2B6 variant alleles and genotype-defined metabolizer phenotypes. METHODS: MEDLINE, EMBASE, Web of Science, Scifinder, PsycINFO, and CENTRAL were screened to identify studies that met the following inclusion criteria (search updated on February 2021): (1) area under the plasma drug concentration-time curve (AUC) of bupropion and/or HB in relation to CYP2B6 genotypes was studied, and (2) study participants were genotyped for common CYP2B6 variant alleles including at least CYP2B6*6. The Newcastle Ottawa Scale was used to assess risk of bias in each included study. The ratio of means (RoM) between CYP2B6 genotype or genotype-defined phenotype groups for bupropion exposure was calculated for each study and combined in a meta-analysis. RESULTS: Eleven studies met the inclusion criteria for this systematic review, and 10 (including N = 413 participants) were included in the meta-analysis. All 10 studies involved healthy adult volunteers, where other medications were not allowed. The AUCs of HB and the active moiety (bupropion + HB) were significantly reduced in CYP2B6*6 carriers compared with the non-carriers (HB: RoM 0.77, 95% CI 0.71-0.83; active moiety: RoM 0.81, 95% CI 0.75-0.88). Both CYP2B6 poor and intermediate metabolizers had significantly decreased exposures to HB and the active moiety than normal metabolizers. CONCLUSION: The CYP2B6*6 allele and genotype-determined CYP2B6 poor and intermediate metabolizer phenotypes are associated with significantly lower exposures to HB and the total active moiety. The findings of this study suggest opportunities to further study precision dosing strategies for bupropion therapy based on CYP2B6 genotype.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Eum S, Sayre F, Lee AM, et al. Association of CYP2B6 genetic polymorphisms with bupropion and hydroxybupropion exposure: A systematic review and meta-analysis. Pharmacotherapy. 2021. PMID: 34752647. doi:10.1002/phar.2644

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。